Macrolide Pharmaceuticals focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens. Using novel technology, Macrolide Pharmaceuticals can synthesize a broad range of macrolides, and initial compounds show promising anti-bacterial activity. The company seeks to extend the anti-bacterial spectrum of the macrolide class, both in Gram-negative infections d and Gram-positive organisms. The synthetic technology provides a platform for the creation of multiple antibiotic products.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/04/15	$22,000,000	Series A	Gurnet Point Capital Novartis Venture Funds Roche Venture Fund SR One	undisclosed
04/02/18	$20,000,000		Advent Life Sciences Gurnet Point Capital Novartis Venture Funds Roche Venture Fund SR One	undisclosed